Organic Active Ingredients TRIZ Cases

Separate active, sweetener, and flavor particles address bitter taste and delayed release in oral powder delivery while improving mouthfeel.

Reboxetine targets cataplexy, daytime sleepiness, concentration, and inadvertent naps through selective norepinephrine inhibition.

Heterocyclic pyrazoles address inadequate type III RTK therapies by inhibiting wildtype and mutant FLT3, PDGFR, c-KIT, and CSF-1R.

Crosslinked MHA hydrogel encapsulates hormone in a dual-chamber syringe, enabling sustained delivery and more consistent dosing.

Age-restricted ENDS devices can block unauthorized use through a security tag that handles identity or age verification.

Precursor-directed biosynthesis and C11 alcohol modification address verticillin’s limited supply and poor solubility while preserving anticancer potency.

Modified oligonucleotides hybridize with KCNT1 RNA to reduce channel activity and address seizures in pharmaco-resistant epilepsies.

Pseudo-irreversible HSD-1 inhibitors form an NADPH-bound complex to lower intracellular cortisol and address tissue-specific morbidity.

Selective M4 allosteric compounds augment receptor activity through a distinct binding site, potentially limiting peripheral side effects.

A lipid pre-formulation creates a liquid crystalline phase in aqueous fluid to sustain prostacyclin release and reduce injection-site irritation.

For non-dialysis CKD anemia, daprodustat raises hemoglobin while delivering clinically relevant fatigue and vitality improvements.

Copper-catalyzed click chemistry links azido targeting ligands to propargyl nucleic acids for flexible PSMA-targeted RNAi delivery.

GalNAc clusters improve gapmer potency and half-life in humans, enabling lower drug amounts and weekly, monthly, or quarterly dosing.

Low-purity oily sonrotoclax intermediate is converted to a stable oxalate solid for scalable production.

APOL1 inhibitors target the disease mechanism behind high-risk genotypes, supporting treatment of chronic kidney disease and diabetic retinopathy.

Short-lived proteases can compromise clotting; lipid nanoparticles deliver siRNA for sustained, controlled fibrinogen reduction.

Allele-specific siRNAs target PNPLA3 mRNA to reduce hepatic triglyceride accumulation and inflammation in NAFLD and related liver disease.

Novel LCMT-1 compounds aim to bypass kinase-related drug resistance by altering PP2A methylation and sensitizing cancer cells to radiation.

Pacritinib targets FLT3 mutations in AML, addressing drug resistance and toxicity concerns linked to earlier multikinase inhibitors.

RE104 HCl prodrug injections address solubility and pharmacokinetic uncertainty while targeting shorter psychedelic experiences.

Modified 19-nor steroids tune GABA receptor chloride conductance to address inconsistent dose response and side effects in CNS treatments.

A separated dosage form releases tegoprazan immediately and NSAIDs in a controlled manner to reduce gastrointestinal side effects while preserving treatment.

Carbonyl-protected intermediates and an SNAr step address low yield and instability, enabling Sonrotoclax synthesis above 70% yield and 90% purity.

Bisphosphonate lipid LNPs bind bone minerals to localize RNA therapeutics, improving delivery to bone and marrow cells while limiting toxicity.

Substituent-tuned gamma-carbolines combine 5-HT2A, dopamine, and mu-opioid activity for potential OCD and OUD treatment.

Engineered CDRs give anti-LY6H antibodies high-affinity binding and enable targeted killing of LY6H-expressing cells.

Calcium ions and cationic lipids support nucleic acid encapsulation and endosomal escape while maintaining controlled particle size for delivery.

BCL6 ligand-directed degraders recruit E3 ligases to trigger ubiquitination and proteasome-mediated removal of the target protein.

Variable R1–R8 substituents tune benzofuran TRPM3 antagonists toward potency with fewer side effects for pain and epilepsy.

Formula-based ionizable lipids help nanoparticles deliver therapeutics beyond the liver to endothelial, mesenchymal, and cancer cells.

Patient-reported outcome questionnaires track dysphagia before and during EoE treatment, while eosinophil counts help assess response.

Specific polyphenols, amino acids, nucleotides, and inulins help mask tectorigenins’ taste and reduce decomposition in oral anti-obesity compositions.

Different-molecular-weight PLGA microparticles encapsulate Tacrolimus for linear release lasting up to two months without an initial burst.

Partial visual-cycle inhibition reduces cytotoxic bisretinoid formation while maintaining sufficient activity to help preserve photoreceptor function.

Follistatin-binding antibodies and small molecules target insulin resistance by reducing follistatin activity and improving insulin sensitivity.

Targeting BTK-C palmitoylation at residues 13 and 16 can block cancer-cell signaling and proliferation while preserving normal immune function.

Crosslinked MHA microbeads address inconsistent hormone dosing by releasing encapsulated hormone steadily in subcutaneous tissue.

A dual-chamber syringe mixes diluent with crosslinked MHA hydrogel to support subcutaneous hormone release and improved absorption.

Water-soluble succinic acid struggles to enter cells; tumor cell-derived microparticles provide targeted delivery with higher loading capacity.

Bifunctional PROTACs recruit E3 ubiquitin ligases to degrade estrogen receptors, addressing tamoxifen’s partial agonism.

Current Alzheimer’s treatments may relieve symptoms without improving cognition; NMDA receptor modulation targets cognitive decline through a disease-focused approach.

Limited treatment options are addressed with small-molecule Formula I inhibitors of plasma kallikrein for angioedema and retinal disorders.

Tranilast formulations target new amyloid fibril formation while promoting dissolution or elimination of existing deposits in vivo.

Negatively charged and bulky oligonucleotides struggle to cross cell membranes; peptide–lipid nanoparticles bind, enter, and release them inside cells.

A wax-matrix, enteric-coated formulation releases 25-hydroxyvitamin D2/D3 in the ileum to maintain stable blood levels.

Immune-suppressive cancers can resist single agents; combining selective HDAC3 inhibition with checkpoint blockade raises MHC class II expression.

Antibody targeting concentrates glucocorticoid receptor agonists at antigen-bearing cells, limiting systemic exposure and side effects.

Adding oxygen to the central ring creates tetrahydropyranopyrazoles with greater metabolic stability and lower CYP inhibition.

Poor solubility and stability limit oral delivery of a CK1α molecular glue degrader; polymer solid dispersions increase exposure.